The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer
Abstract
Purpose: The paclitaxel, fluorouracil, and hydroxyurea regimen of paclitaxel, infusional fluorouracil, hydroxyurea, and twice-daily radiation therapy (TFHX) administered every other week has resulted in 3-year survival rates of 60% of stage IV patients. Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX. Patients and Methods: Sixty-nine patients received six weekly doses of carboplatin (AUC2) and paclitaxel (135 mg/m 2) followed by five cycles of TFHX. Results: Ninety-six percent had stage IV disease. Response to induction chemotherapy was partial response 52% and complete response (CR) 35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most common grade 3 or 4 toxicity was neutropenia (36%). Best response following completion of TFHX was CR in 83%. Toxicities of TFHX consisted of grade 3 or 4 mucositis (74% and 2%) and dermatitis (47% and 14%). At a median follow-up of 28 months, locoregional or systemic disease progression were each noted in five patients. The overall 3-year progression-free survival was 80% (95% confidence interval [CI], 71% to 90%), and the 2- and 3-year overall survival rates were 77% (95% CI, 66% to 87%) and 70% (95% CI, 59% to 82%), respectively. At 12 months, five patients were completely feeding-tube dependent. Conclusion: Administration of carboplatin and paclitaxel before TFHX chemoradiotherapy results in high response activity and may decrease distant failure rates. Overall survival, progression, and organ preservation/functional outcome data support definitive evaluation of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cited by
Eisbruch, A., Schwartz, M., Rasch, C., Vineberg, K., Damen, E., Van As, C. J., Marsh, R., Pameijer, F. A., & Balm, A. J. M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.050 · Cited by 658
Cohen, E. E. W., Karrison, T. G., Kocherginsky, M., Mueller, J., Egan, R., Huang, C. H., Brockstein, B. E., Agulnik, M. B., Mittal, B. B., Yunus, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.6309 · Cited by 571
Self-citationPredictors of Competing Mortality in Advanced Head and Neck Cancer
Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9288 · Cited by 433
Self-citationPfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Self-citationBrockstein, B., Haraf, D. J., Rademaker, A. W., Kies, M. S., Stenson, K. M., Rosen, F., Mittal, B. B., Pelzer, H., Fung, B. B., Witt, M.-E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh308 · Cited by 370
Self-citation
Metadata
- Authors
- Vokes, E. E., Stenson, K., Rosen, F. R., Kies, M. S., Rademaker, A. W., Witt, M. E., Brockstein, B. E., List, M. A., Fung, B. B., Portugal, L., Mittal, B. B., Pelzer, H., Weichselbaum, R. R., & Haraf, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-15
- Volume
- 21
- Issue
- 2
- Pages
- 320-326
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103151974
- Cited by
- 234
- References
- 2
- FWCI
- 36.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer. https://app.cochat.ai/papers/10.1200/jco.2003.06.006
- The paper
- Vokes, E. E., Stenson, K., Rosen, F. R., Kies, M. S., Rademaker, A. W., Witt, M. E., Brockstein, B. E., List, M. A., Fung, B. B., Portugal, L., Mittal, B. B., Pelzer, H., Weichselbaum, R. R., & Haraf, D. J. (2003). Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.